Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Buck

Showing results (691-700 of 700) with videos related to

Pageof 70
Sort By:
You have reached the last page of results.This site can display upto 700 results.
Journal of Medicinal Chemistry|September 14, 2007
Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonistsIain M McDonald, Carol Austin, Ildiko M Buck, et al.
ACS Medicinal Chemistry Letters|October 20, 2022
Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 InhibitorEmiliano Tamanini, Shin Miyamura, Ildiko M Buck, et al.
Journal of Medical Virology|November 21, 2023
The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptomsAmanda M Buck, Amelia N Deitchman, Saki Takahashi, et al.
Journal of Medicinal Chemistry|June 1, 2007
Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretionIain M McDonald, James W Black, Ildiko M Buck, et al.
Journal of Medicinal Chemistry|October 28, 2005
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonistsIldiko M Buck, James W Black, Tracey Cooke, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 8, 2021
FutureTox IV Workshop Summary: Predictive Toxicology for Healthy ChildrenThomas B Knudsen, Suzanne Compton Fitzpatrick, K Nadira De Abrew, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19Michael J Peluso, Dylan Ryder, Robert Flavell, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Science Translational Medicine|July 3, 2024
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infectionMichael J Peluso, Dylan Ryder, Robert R Flavell, et al.
Pageof 70

Showing results (691-700 of 700) with videos related to

Sort By:
Pageof 70
You have reached the last page of results.This site can display upto 700 results.
Journal of Medicinal Chemistry|September 14, 2007
Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonistsIain M McDonald, Carol Austin, Ildiko M Buck, et al.
ACS Medicinal Chemistry Letters|October 20, 2022
Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 InhibitorEmiliano Tamanini, Shin Miyamura, Ildiko M Buck, et al.
Journal of Medical Virology|November 21, 2023
The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptomsAmanda M Buck, Amelia N Deitchman, Saki Takahashi, et al.
Journal of Medicinal Chemistry|June 1, 2007
Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretionIain M McDonald, James W Black, Ildiko M Buck, et al.
Journal of Medicinal Chemistry|October 28, 2005
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonistsIldiko M Buck, James W Black, Tracey Cooke, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 8, 2021
FutureTox IV Workshop Summary: Predictive Toxicology for Healthy ChildrenThomas B Knudsen, Suzanne Compton Fitzpatrick, K Nadira De Abrew, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19Michael J Peluso, Dylan Ryder, Robert Flavell, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Science Translational Medicine|July 3, 2024
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infectionMichael J Peluso, Dylan Ryder, Robert R Flavell, et al.
Pageof 70